Globally, Ono Pharmaceutical Co., Ltd., along with its affiliated entities, is engaged in the development, procurement, and commercialization of pharmaceutical products and diagnostic tools. Its product line features a wide array of therapeutic solutions, including several key oncology treatments such as OPDIVO, KYPROLIS, MEKTOVI, VELEXBRU, ADLUMIZ, and BRAFTOVI. It also offers EMEND and PROEMEND for managing chemotherapy-induced nausea and vomiting, and DEMSER for pheochromocytoma symptoms. For metabolic health, GLACTIV and FORXIGA target type 2 diabetes. The company provides medications for cardiovascular conditions (ONOACT for tachyarrhythmia, OPALMON for peripheral circulatory disorder, CORALAN for chronic heart failure) and autoimmune diseases (ORENCIA for rheumatoid arthritis). Neurological disorders are addressed with RIVASTACH for Alzheimer's and ONGENTYS for Parkinson's disease. Other significant offerings cover conditions such as overactive bladder (STAYBLA), bronchial asthma and allergic rhinitis (ONON), osteoporosis (RECALBON), and joint function improvement (JOYCLU), alongside PARSABIV for dialysis patients. Beyond its existing portfolio, the company maintains an active research and development pipeline, focusing on numerous therapeutic areas. This includes a broad spectrum of oncological conditions, such as various carcinomas (esophageal, urothelial, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, non-small cell lung), lymphomas (Hodgkin's, primary central nervous system), melanoma, acute myeloid leukemia, myelodysplastic syndrome, and virus-positive/negative solid tumors. Its developmental efforts also extend to inflammatory and autoimmune disorders like polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy, as well as cardiovascular issues (tachyarrhythmia, thrombosis), neurodegenerative diseases, diabetic polyneuropathy, and conditions such as narcolepsy. Established in 1717, this long-standing enterprise operates from its main office in Osaka, Japan.
—
Globally, Ono Pharmaceutical Co., Ltd., along with its affiliated entities, is engaged in the development, procurement, and commercialization of pharmaceutical products and diagnostic tools. Its product line features a wide array of therapeutic solutions, including several key oncology treatments such as OPDIVO, KYPROLIS, MEKTOVI, VELEXBRU, ADLUMIZ, and BRAFTOVI. It also offers EMEND and PROEMEND for managing chemotherapy-induced nausea and vomiting, and DEMSER for pheochromocytoma symptoms. For metabolic health, GLACTIV and FORXIGA target type 2 diabetes. The company provides medications for cardiovascular conditions (ONOACT for tachyarrhythmia, OPALMON for peripheral circulatory disorder, CORALAN for chronic heart failure) and autoimmune diseases (ORENCIA for rheumatoid arthritis). Neurological disorders are addressed with RIVASTACH for Alzheimer's and ONGENTYS for Parkinson's disease. Other significant offerings cover conditions such as overactive bladder (STAYBLA), bronchial asthma and allergic rhinitis (ONON), osteoporosis (RECALBON), and joint function improvement (JOYCLU), alongside PARSABIV for dialysis patients. Beyond its existing portfolio, the company maintains an active research and development pipeline, focusing on numerous therapeutic areas. This includes a broad spectrum of oncological conditions, such as various carcinomas (esophageal, urothelial, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, non-small cell lung), lymphomas (Hodgkin's, primary central nervous system), melanoma, acute myeloid leukemia, myelodysplastic syndrome, and virus-positive/negative solid tumors. Its developmental efforts also extend to inflammatory and autoimmune disorders like polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy, as well as cardiovascular issues (tachyarrhythmia, thrombosis), neurodegenerative diseases, diabetic polyneuropathy, and conditions such as narcolepsy. Established in 1717, this long-standing enterprise operates from its main office in Osaka, Japan.
—
Daily adjusted close
Globally, Ono Pharmaceutical Co., Ltd., along with its affiliated entities, is engaged in the development, procurement, and commercialization of pharmaceutical products and diagnostic tools. Its product line features a wide array of therapeutic solutions, including several key oncology treatments such as OPDIVO, KYPROLIS, MEKTOVI, VELEXBRU, ADLUMIZ, and BRAFTOVI. It also offers EMEND and PROEMEND for managing chemotherapy-induced nausea and vomiting, and DEMSER for pheochromocytoma symptoms. For metabolic health, GLACTIV and FORXIGA target type 2 diabetes. The company provides medications for cardiovascular conditions (ONOACT for tachyarrhythmia, OPALMON for peripheral circulatory disorder, CORALAN for chronic heart failure) and autoimmune diseases (ORENCIA for rheumatoid arthritis). Neurological disorders are addressed with RIVASTACH for Alzheimer's and ONGENTYS for Parkinson's disease. Other significant offerings cover conditions such as overactive bladder (STAYBLA), bronchial asthma and allergic rhinitis (ONON), osteoporosis (RECALBON), and joint function improvement (JOYCLU), alongside PARSABIV for dialysis patients. Beyond its existing portfolio, the company maintains an active research and development pipeline, focusing on numerous therapeutic areas. This includes a broad spectrum of oncological conditions, such as various carcinomas (esophageal, urothelial, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, non-small cell lung), lymphomas (Hodgkin's, primary central nervous system), melanoma, acute myeloid leukemia, myelodysplastic syndrome, and virus-positive/negative solid tumors. Its developmental efforts also extend to inflammatory and autoimmune disorders like polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy, as well as cardiovascular issues (tachyarrhythmia, thrombosis), neurodegenerative diseases, diabetic polyneuropathy, and conditions such as narcolepsy. Established in 1717, this long-standing enterprise operates from its main office in Osaka, Japan.